Skip to main content
. 2022 Oct 17;9(1):85–93. doi: 10.1093/ehjcvp/pvac054

Graphical Abstract.

Graphical Abstract

Finerenone reduced the risk of clinically important cardiorenal outcomes vs. placebo, irrespective of history of atherosclerotic cardiovascular disease, across the spectrum of chronic kidney disease in patients with type 2 diabetes.